Loading...

Bavarian Nordic

CPSE:BAVA
Snowflake Description

Exceptional growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
BAVA
CPSE
DKK4B
Market Cap
  1. Home
  2. DK
  3. Pharmaceuticals & Biotech
Company description

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The last earnings update was 59 days ago. More info.


Add to Portfolio Compare Print
BAVA Share Price and Events
7 Day Returns
-0.6%
CPSE:BAVA
4.8%
DK Biotechs
-0.7%
DK Market
1 Year Returns
-33.4%
CPSE:BAVA
-9.4%
DK Biotechs
-0.8%
DK Market
BAVA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Bavarian Nordic (BAVA) -0.6% -0.9% -10.4% -33.4% -45.2% 11.4%
DK Biotechs 4.8% 2.6% 12.5% -9.4% -2% 319.5%
DK Market -0.7% -1.3% 1.1% -0.8% 4% 36.9%
1 Year Return vs Industry and Market
  • BAVA underperformed the Biotechs industry which returned -9.4% over the past year.
  • BAVA underperformed the Market in Denmark which returned -0.8% over the past year.
Price Volatility
BAVA
Industry
5yr Volatility vs Market

BAVA Value

 Is Bavarian Nordic undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Bavarian Nordic. This is due to cash flow or dividend data being unavailable. The share price is DKK135.95.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Bavarian Nordic's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Bavarian Nordic's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CPSE:BAVA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in DKK DKK-11.22
CPSE:BAVA Share Price ** CPSE (2019-05-16) in DKK DKK135.95
Europe Biotechs Industry PE Ratio Median Figure of 29 Publicly-Listed Biotechs Companies 22.03x
Denmark Market PE Ratio Median Figure of 103 Publicly-Listed Companies 16.24x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Bavarian Nordic.

CPSE:BAVA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CPSE:BAVA Share Price ÷ EPS (both in DKK)

= 135.95 ÷ -11.22

-12.12x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bavarian Nordic is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Bavarian Nordic is loss making, we can't compare the value of its earnings to the Denmark market.
Price based on expected Growth
Does Bavarian Nordic's expected growth come at a high price?
Raw Data
CPSE:BAVA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -12.12x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
37%per year
Europe Biotechs Industry PEG Ratio Median Figure of 23 Publicly-Listed Biotechs Companies 1.29x
Denmark Market PEG Ratio Median Figure of 44 Publicly-Listed Companies 2.16x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Bavarian Nordic, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Bavarian Nordic's assets?
Raw Data
CPSE:BAVA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in DKK DKK67.60
CPSE:BAVA Share Price * CPSE (2019-05-16) in DKK DKK135.95
Denmark Biotechs Industry PB Ratio Median Figure of 6 Publicly-Listed Biotechs Companies 3.29x
Denmark Market PB Ratio Median Figure of 134 Publicly-Listed Companies 1.64x
CPSE:BAVA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CPSE:BAVA Share Price ÷ Book Value per Share (both in DKK)

= 135.95 ÷ 67.60

2.01x

* Primary Listing of Bavarian Nordic.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Bavarian Nordic is good value based on assets compared to the DK Biotechs industry average.
X
Value checks
We assess Bavarian Nordic's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Bavarian Nordic has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

BAVA Future Performance

 How is Bavarian Nordic expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
37%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Bavarian Nordic expected to grow at an attractive rate?
  • Bavarian Nordic's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Bavarian Nordic's earnings growth is expected to exceed the Denmark market average.
  • Bavarian Nordic's revenue growth is expected to exceed the Denmark market average.
Annual Growth Rates Comparison
Raw Data
CPSE:BAVA Future Growth Rates Data Sources
Data Point Source Value (per year)
CPSE:BAVA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 37%
CPSE:BAVA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 26%
Denmark Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 23.8%
Europe Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 14.3%
Denmark Market Earnings Growth Rate Market Cap Weighted Average 11.9%
Denmark Market Revenue Growth Rate Market Cap Weighted Average 6.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CPSE:BAVA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in DKK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CPSE:BAVA Future Estimates Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 1,744 -132 -266 2
2022-12-31 1,832 546 346 2
2021-12-31 1,668 -167 -156 4
2020-12-31 897 238 12 7
2019-12-31 601 -325 -337 6
CPSE:BAVA Past Financials Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income *
2018-12-31 501 -289 -362
2018-09-30 360 -467 -445
2018-06-30 873 -564 -151
2018-03-31 1,184 -158 5
2017-12-31 1,370 216 181
2017-09-30 1,745 1,030 453
2017-06-30 1,463 880 225
2017-03-31 1,182 501 153
2016-12-31 1,007 268 31
2016-09-30 909 -539 -54
2016-06-30 536 -345 -202
2016-03-31 808 -561 -115

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Bavarian Nordic's earnings are expected to grow significantly at over 20% yearly.
  • Bavarian Nordic's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CPSE:BAVA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Bavarian Nordic Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CPSE:BAVA Future Estimates Data
Date (Data in DKK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -8.00 -8.00 -8.00 1.00
2022-12-31 10.30 10.30 10.30 1.00
2021-12-31 9.68 15.89 -1.30 3.00
2020-12-31 -0.01 5.75 -12.90 4.00
2019-12-31 -11.08 -10.27 -11.47 4.00
CPSE:BAVA Past Financials Data
Date (Data in DKK Millions) EPS *
2018-12-31 -11.22
2018-09-30 -13.82
2018-06-30 -4.72
2018-03-31 0.16
2017-12-31 5.73
2017-09-30 14.45
2017-06-30 7.21
2017-03-31 4.96
2016-12-31 1.02
2016-09-30 -1.86
2016-06-30 -7.09
2016-03-31 -4.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Bavarian Nordic is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Bavarian Nordic's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Denmark market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Bavarian Nordic has a total score of 6/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

BAVA Past Performance

  How has Bavarian Nordic performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Bavarian Nordic's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Bavarian Nordic does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Bavarian Nordic's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Bavarian Nordic's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Bavarian Nordic's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Bavarian Nordic Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CPSE:BAVA Past Revenue, Cash Flow and Net Income Data
Date (Data in DKK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 500.62 -361.93 213.68 386.30
2018-09-30 360.27 -445.11 217.53 421.79
2018-06-30 872.81 -151.16 209.31 511.26
2018-03-31 1,183.75 4.95 205.98 534.74
2017-12-31 1,370.15 181.34 207.94 518.41
2017-09-30 1,744.57 453.23 204.96 511.98
2017-06-30 1,462.60 225.38 214.17 481.61
2017-03-31 1,181.88 153.30 211.06 459.16
2016-12-31 1,006.74 30.60 212.77 463.17
2016-09-30 908.96 -54.40 215.45 402.39
2016-06-30 535.76 -201.85 204.49 349.06
2016-03-31 808.33 -114.70 204.85 372.56
2015-12-31 1,020.56 59.43 217.06 374.81
2015-09-30 1,244.24 155.09 229.05 462.30
2015-06-30 1,390.33 186.38 244.45 506.52
2015-03-31 1,165.70 70.12 241.64 496.20
2014-12-31 1,216.82 25.94 226.13 478.93
2014-09-30 1,013.09 -98.87 203.90 425.09
2014-06-30 1,106.80 -61.33 197.57 405.91
2014-03-31 1,292.70 -11.73 197.97 512.41
2013-12-31 1,212.50 -46.73 197.77 496.61
2013-09-30 1,141.84 -82.00 220.84 500.62
2013-06-30 1,127.34 -81.40 215.04 478.92
2013-03-31 1,054.54 -244.50 204.44 346.12
2012-12-31 1,016.64 -240.00 194.64 340.12
2012-09-30 1,118.50 -169.62 182.25 299.02
2012-06-30 911.20 -239.62 173.25 285.42

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Bavarian Nordic has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Bavarian Nordic has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Bavarian Nordic improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Bavarian Nordic's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Bavarian Nordic has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

BAVA Health

 How is Bavarian Nordic's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Bavarian Nordic's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Bavarian Nordic is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Bavarian Nordic's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Bavarian Nordic's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Bavarian Nordic Company Filings, last reported 4 months ago.

CPSE:BAVA Past Debt and Equity Data
Date (Data in DKK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 2,180.63 646.88 2,317.21
2018-09-30 2,278.54 649.36 2,408.69
2018-06-30 2,249.83 689.41 2,479.79
2018-03-31 2,333.05 512.27 2,446.05
2017-12-31 2,506.30 402.04 2,583.72
2017-09-30 2,637.39 30.27 2,416.17
2017-06-30 2,122.61 30.79 2,312.58
2017-03-31 2,039.77 31.39 2,056.39
2016-12-31 2,017.24 32.11 1,899.90
2016-09-30 1,914.60 32.52 1,254.52
2016-06-30 1,804.48 32.32 1,502.04
2016-03-31 1,212.43 32.81 972.03
2015-12-31 1,342.48 33.29 1,058.20
2015-09-30 1,302.66 33.77 1,233.91
2015-06-30 1,348.80 34.20 1,285.00
2015-03-31 1,268.90 34.70 1,607.50
2014-12-31 1,252.09 35.18 979.71
2014-09-30 881.50 77.50 236.10
2014-06-30 925.00 76.40 303.50
2014-03-31 978.70 78.20 414.90
2013-12-31 976.29 80.32 532.08
2013-09-30 996.60 83.30 431.30
2013-06-30 966.10 85.20 574.60
2013-03-31 961.50 88.70 423.00
2012-12-31 999.68 90.11 549.90
2012-09-30 1,052.30 92.60 546.40
2012-06-30 1,019.70 96.20 511.30
  • Bavarian Nordic's level of debt (29.7%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (8.2% vs 29.7% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Information is not available.
  • Unable to confirm if Bavarian Nordic has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Bavarian Nordic's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Bavarian Nordic has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

BAVA Dividends

 What is Bavarian Nordic's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Bavarian Nordic dividends. Estimated to be 0% next year.
If you bought DKK2,000 of Bavarian Nordic shares you are expected to receive DKK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Bavarian Nordic's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Bavarian Nordic's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CPSE:BAVA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Denmark Market Average Dividend Yield Market Cap Weighted Average of 78 Stocks 2.5%
Denmark Minimum Threshold Dividend Yield 10th Percentile 1%
Denmark Bottom 25% Dividend Yield 25th Percentile 1.6%
Denmark Top 25% Dividend Yield 75th Percentile 4.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CPSE:BAVA Future Dividends Estimate Data
Date (Data in DKK) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Bavarian Nordic has not reported any payouts.
  • Unable to verify if Bavarian Nordic's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Bavarian Nordic's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Bavarian Nordic has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Bavarian Nordic's dividends in 3 years as they are not expected to pay a notable one for Denmark.
X
Income/ dividend checks
We assess Bavarian Nordic's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Bavarian Nordic afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Bavarian Nordic has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

BAVA Management

 What is the CEO of Bavarian Nordic's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Chaplin
COMPENSATION DKK8,317,000
AGE 51
TENURE AS CEO 4.9 years
CEO Bio

Dr. Paul Chaplin MSc, Ph.D. has been the Chief Executive Officer and President at Bavarian Nordic A/S since May 28, 2014. Dr. Chaplin served as an Executive Vice President of Bavarian Nordic A/S from 2004 to May 28, 2014 and served as its Division President of Infectious Diseases until May 28, 2014. Dr. Chaplin served as the President of Infectious Diseases Division of Research & Development of Bavarian Nordic A/S. Dr. Chaplin served as the Chief Scientific Officer of Bavarian Nordic A/S. He served as Vice President, Research and Development of Bavarian Nordic A/S. He served as Managing Director of Bavarian Nordic GmbH. Dr. Chaplin served as General Manager of German Subsidiary of Bavarian Nordic Research Institute AS. Dr. Chaplin joined Bavarian Nordic A/S in 1999 as Manager of Immunology. Dr. Chaplin worked for several years at the Institute for Animal Health in the UK in the areas of cytokine and dendritic cell biology. Dr. Chaplin was involved in research and development of veterinary vaccines at CSIRO, the Cooperative Research Centre for Vaccine Technology in Australia for three years. Dr. Chaplin holds a PhD from Bristol University.

CEO Compensation
  • Paul's compensation has been consistent with company performance over the past year.
  • Paul's remuneration is about average for companies of similar size in Denmark.
Management Team Tenure

Average tenure and age of the Bavarian Nordic management team in years:

2.1
Average Tenure
48
Average Age
  • The tenure for the Bavarian Nordic management team is about average.
Management Team

Paul Chaplin

TITLE
CEO & President
COMPENSATION
DKK8M
AGE
51
TENURE
4.9 yrs

Henrik Juuel

TITLE
CFO & Executive VP
COMPENSATION
DKK4M
AGE
53
TENURE
0.5 yrs

Henrik Birk

TITLE
COO & Executive VP
COMPENSATION
DKK4M
AGE
44
TENURE
2.3 yrs

Tommi Kainu

TITLE
Executive VP & Chief Business Officer
COMPENSATION
DKK4M
AGE
45
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure and age of the Bavarian Nordic board of directors in years:

5.1
Average Tenure
61
Average Age
  • The tenure for the Bavarian Nordic board of directors is about average.
Board of Directors

Gerard W. van Odijk

TITLE
Chairman
COMPENSATION
DKK1M
AGE
61
TENURE
5.1 yrs

Anders Pedersen

TITLE
Deputy Chairman
COMPENSATION
DKK843K
AGE
67
TENURE
5.1 yrs

Erik Hansen

TITLE
Independent Director
COMPENSATION
DKK668K
AGE
66
TENURE
9.1 yrs

Peter Kürstein-Jensen

TITLE
Independent Director
COMPENSATION
DKK608K
AGE
62
TENURE
7.1 yrs

Frank A. G. Verwiel

TITLE
Independent Director
COMPENSATION
DKK747K
AGE
56
TENURE
3.1 yrs

Liz Anderson

TITLE
Independent Director
COMPENSATION
DKK633K
AGE
61
TENURE
2.1 yrs

Anne Eberhard

TITLE
Independent Director
AGE
55
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (DKK) Value (DKK)
X
Management checks
We assess Bavarian Nordic's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Bavarian Nordic has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

BAVA News

Simply Wall St News

What Kind Of Shareholders Own Bavarian Nordic A/S (CPH:BAVA)?

With a market capitalization of ø4.4b, Bavarian Nordic is a small cap stock, so it might not be well known by many institutional investors. … Insider Ownership Of Bavarian Nordic The definition of company insiders can be subjective, and does vary between jurisdictions. … General Public Ownership The general public, who are mostly retail investors, collectively hold 84% of Bavarian Nordic shares.

Simply Wall St -

Volatility 101: Should Bavarian Nordic (CPH:BAVA) Shares Have Dropped 45%?

While it may not be enough for some shareholders, we think it is good to see the Bavarian Nordic A/S (CPH:BAVA) share price up 11% in a single quarter. … Bavarian Nordic isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … Over the last three years, Bavarian Nordic's revenue dropped 4.2% per year.

Simply Wall St -

How Should Investors Feel About Bavarian Nordic A/S's (CPH:BAVA) CEO Pay?

In 2014 Paul Chaplin was appointed CEO of Bavarian Nordic A/S (CPH:BAVA). … First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Paul Chaplin's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Do Institutions Own Shares In Bavarian Nordic A/S (CPH:BAVA)?

Generally speaking, as a company grows, institutions will increase their ownership. … Our analysis of the ownership of the company, below, shows that. … institutions own shares in the company.

Simply Wall St -

How Much Did Bavarian Nordic A/S's (CPH:BAVA) CEO Pocket Last Year?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Paul Chaplin's Compensation Compare With Similar Sized Companies. … As you can see, Paul Chaplin is paid more than the median CEO pay at companies of a similar size, in the same market

Simply Wall St -

Why Bavarian Nordic A/S's (CPH:BAVA) Ownership Structure Is Important

In this article, I'm going to take a look at Bavarian Nordic A/S’s (CPH:BAVA) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders.

Simply Wall St -

Will Bavarian Nordic A/S (CPH:BAVA) Continue To Underperform Its Industry?

and want to better understand how you can grow your money by investing in Bavarian Nordic A/S (CPH:BAVA). … Bavarian Nordic A/S (CPH:BAVA) generated a below-average return on equity of 0.21% in the past 12 months, while its industry returned 16.96%. … An investor may attribute an inferior ROE to a relatively inefficient performance, and whilst this can often be the case, knowing the nuts and bolts of the ROE calculation may change that perspective and give you a deeper insight into BAVA's past performance

Simply Wall St -

Will Bavarian Nordic A/S's (CPH:BAVA) Earnings Grow In The Years Ahead?

The most recent earnings release Bavarian Nordic A/S's (CPSE:BAVA) announced in December 2017 confirmed that the company benefited from a major tailwind, more than doubling its earnings from the prior year. … Today I want to provide a brief commentary on how market analysts perceive Bavarian Nordic's earnings growth trajectory over the next couple of years and whether the future looks even brighter than the past. … This means, we can presume Bavarian Nordic will grow its earnings by 33.21% every year for the next couple of years.

Simply Wall St -

Bavarian Nordic A/S (CPH:BAVA): Strong Health, Poor Growth

Bavarian Nordic A/S (CPSE:BAVA) has been on my radar for a while, and my main concern is around the sustainability of the business going forward. … A reason I like BAVA as a business is its low level of fixed assets on its balance sheet (14.59% of total assets). … BAVA has virtually no fixed assets, which minimizes its downside risk.

Simply Wall St -

Investors Are Undervaluing Bavarian Nordic A/S (CPH:BAVA) By 22%

In this article I am going to calculate the intrinsic value of Bavarian Nordic A/S (CPSE:BAVA) by taking the expected future cash flows and discounting them to their present value. … 5-year cash flow forecast 2018 2019 2020 2021 2022 Levered FCF (DKK, Millions) DKK-456.00 DKK83.00 DKK276.00 DKK339.00 DKK799.00 Source Analyst x2 Analyst x1 Analyst x1 Analyst x1 Analyst x1 Present Value Discounted @ 8.15% DKK-421.64 DKK70.96 DKK218.20 DKK247.81 DKK540.07 Present Value of 5-year Cash Flow (PVCF)= DKK655 The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. … CPSE:BAVA Intrinsic Value Mar 23rd 18 Important assumptions I'd like to point out that the most important inputs to a discounted cash flow are the discount rate and of course the actual cash flows.

Simply Wall St -

BAVA Company Info

Description

Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus. In addition, the company develops MVA-BN HIV, a preclinical stage human immunodeficiency virus (HIV) vaccine candidate; MVA-BN HBV, a preclinical stage hepatitis B vaccine candidate; CV301 that is in various clinical trials for the treatment of bladder, colorecta, and pancreatic and colorectal cancers; and MVA-BN Brachyury that is in Phase II clinical trials for the treatment of chordoma and other metastatic cancers. It has license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, the Netherlands, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is based in Kvistgård, Denmark.

Details
Name: Bavarian Nordic A/S
BAVA
Exchange: CPSE
Founded: 1994
DKK4,385,732,317
32,259,892
Website: http://www.bavarian-nordic.com
Address: Bavarian Nordic A/S
Hejreskovvej 10A,
Kvistgård,
Capital Region of Denmark, 3490,
Denmark
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CPSE BAVA Ordinary Shares OMX Nordic Exchange Copenhagen DK DKK 05. Nov 1998
OTCPK BVNK.F Ordinary Shares Pink Sheets LLC US USD 05. Nov 1998
DB BV3 Ordinary Shares Deutsche Boerse AG DE EUR 05. Nov 1998
LSE 0DPB Ordinary Shares London Stock Exchange GB DKK 05. Nov 1998
BATS-CHIXE BAVAC Ordinary Shares BATS 'Chi-X Europe' GB DKK 05. Nov 1998
OTCPK BVNR.Y SPONSORED ADR Pink Sheets LLC US USD 30. May 2013
Number of employees
Current staff
Staff numbers
419
Bavarian Nordic employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/19 20:37
End of day share price update: 2019/05/16 00:00
Last estimates confirmation: 2019/04/16
Last earnings filing: 2019/03/21
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.